Home Tags Aviceda Therapeutics

Aviceda Therapeutics

Aviceda Therapeutics (“Aviceda”), a private, clinical-stage biotech company announced the closing of a $207.5 million Series C financing. Proceeds will support the ongoing Phase 2b/3 and planned pivotal Phase 3 clinical trial for AVD-104 in geographic atrophy (GA), a vision-threatening condition secondary to advanced age-related macular degeneration, and the expansion into other ophthalmic indications.

Aviceda Therapeutics Raises $207.5 Mn in Series C Financing Round

Team SR -
© Copyright startuprise 2024 All Rights Reserved.
Exit mobile version